SPACE
Single-Arm Phase II-Study in Patients with extensive stage small cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide
II
interventionell
International
Atezolizumab, Carboplatin, Etoposide
Status: Rekrutierung beendet
Zeitraum
2020
2023
Zentren
20
20
Patienten
70
70
17.10.2023
Klinische Settings
IV
palliativ
Identifier
AIO-TRK-0119
AIO-TRK-0119
2019-001707-21
Kontakt
Leitung
Prof. Dr. med. Martin Reck
Ansprechpartner*in
Dr. Tim Overkamp
Telefon +49 30 814534442
E-Mail SPACE@aio-studien-ggmbh.de